Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1

Inclusion Criteria: * Body weight ≤ 90kg * Ability to understand and the willingness to sign a written informed consent document * Study subject must have read, understood, and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained * Be in general good health without history of any of the conditions listed in exclusion criteria * No use of any tobacco products for at least 6 months * Woman/women of childbearing potential (WOCBP) must agree not to become pregnant from the time of study enrollment until at least 6 months after the completion of the monoclonal antibody infusion. If a WOCBP is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel * Sexually active male subjects must use a barrier method of contraception during the study * Screening laboratory values must meet the following criteria: * WBC (\>3,000 - \<11,000/mm\^3) * Platelets (\>100,000/mm\^3) * Hemoglobin (\>10.5 gm/dl) * Creatinine (\<1.1 x upper limit of normal \[ULN\]) * BUN (\<1.25 x ULN) * AST (\<1.1 x ULN) * ALT (\<1.1 x ULN) * Alkaline Phosphatase (\<1.1 x ULN) * Bilirubin (\<1.1 x ULN) * Glucose-non-fasting (\> 60 mg/dl and \< 115 mg/dl) * Human immunodeficiency virus (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial * For subjects with evidence of …